The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease

Completed

• Conditions: Obesity; Metabolic Disease

• Registration Number: NCT03164005
• Lead Sponsor: Wuhan Union Hospital, China

Brief Summary

The investigators will enroll about 120 subjects from the hospital's healthcare center. The investigators will collect the basic informations, blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject. The investigators will collect the blood samples and then test them for fasting insulin levels, VEGF-B levels, the gene promoter region methylation status and the genomic protein methylation levels of the VEGF-B gene of the cells，and finally do the statistical analysis.

Detailed Description

The investigators will enroll about 120 subjects from the hospital's healthcare center, and these 120 subjects will be divided into four groups: normal weight with or without metabolic diseases and obesity with or without metabolic diseases. Each group has 30 subjects. The investigators will collect the basic information(name, gender，age, medical history，family history, etc.), blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject from the healthcare center. The investigators will collect the blood samples of each subject,separate the plasma and then test the fasting insulin, VEGF-B levels by ELISA. The investigators will separate the peripheral blood mononuclear cells from the blood, and then test the gene promoter region methylation status of the VEGF -B gene by PCR and the bisulfite-modified sequencing and test the genomic protein methylation level of the VEGF-B gene by chromatin immunoprecipitation assay(CHIP) and real-time quantitative PCR of the cells，and finally do the statistical analysis.

Study Timeline

• Study Start: 2017-04-20
• Study First Submitted: 2017-05-13
• Study First Submitted QC: 2017-05-21
• Study First Posted: 2017-05-23
• Primary Completion: 2017-09-01
• Study Completion: 2018-03-01
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-05
• Last Update Posted: 2021-04-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 194

Inclusion Criteria

• NA

Exclusion Criteria

• subjects with active history insulin treatment; and female participant pregnant at the time of recruitment.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting insulin and blood VEGF-B levels	3 days	To investigate the relationship between blood pressure, BMI, fasting blood glucose, fasting blood lipids and fasting insulin and blood VEGF-B levels.

Secondary Outcome Measures

Name	Time	Method
The methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level .	7 days	To investigate the relationship between the methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level and obesity and metabolic disorders.

Trial Locations

Locations (1)

Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China